MGX Stock Overview
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Metagenomi, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.48 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$1.23 |
| Beta | 0 |
| 1 Month Change | -23.71% |
| 3 Month Change | -46.38% |
| 1 Year Change | -82.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.65% |
Recent News & Updates
Recent updates
Metagenomi, Inc.'s (NASDAQ:MGX) 26% Dip In Price Shows Sentiment Is Matching Revenues
Mar 16
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential
Jan 28The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26%
Jan 28We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully
Jan 14Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry
Dec 10Shareholder Returns
| MGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.5% | 1.3% | 5.8% |
| 1Y | -82.7% | -11.3% | 4.8% |
Return vs Industry: MGX underperformed the US Biotechs industry which returned -11.3% over the past year.
Return vs Market: MGX underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| MGX volatility | |
|---|---|
| MGX Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: MGX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MGX's weekly volatility has decreased from 22% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 202 | Brian Thomas | metagenomi.co |
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer.
Metagenomi, Inc. Fundamentals Summary
| MGX fundamental statistics | |
|---|---|
| Market cap | US$55.33m |
| Earnings (TTM) | -US$78.06m |
| Revenue (TTM) | US$52.30m |
1.1x
P/S Ratio-0.7x
P/E RatioIs MGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGX income statement (TTM) | |
|---|---|
| Revenue | US$52.30m |
| Cost of Revenue | US$109.18m |
| Gross Profit | -US$56.88m |
| Other Expenses | US$21.17m |
| Earnings | -US$78.06m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | -108.78% |
| Net Profit Margin | -149.26% |
| Debt/Equity Ratio | 0% |
How did MGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 07:59 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metagenomi, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |